Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Insider and Institutional Ownership
5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by company insiders. Comparatively, 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Firefly Neuroscience has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
| Aclarion | 1 | 0 | 1 | 0 | 2.00 |
Aclarion has a consensus price target of $7.50, indicating a potential upside of 194.12%. Given Aclarion’s stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.
Profitability
This table compares Firefly Neuroscience and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Firefly Neuroscience | -506.23% | -90.17% | -72.05% |
| Aclarion | -10,948.81% | -59.34% | -56.12% |
Valuation & Earnings
This table compares Firefly Neuroscience and Aclarion”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Firefly Neuroscience | $1.14 million | 12.80 | -$19.88 million | ($0.59) | -1.58 |
| Aclarion | $80,000.00 | 91.80 | -$7.23 million | ($7.40) | -0.34 |
Aclarion has lower revenue, but higher earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Summary
Aclarion beats Firefly Neuroscience on 10 of the 14 factors compared between the two stocks.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for Firefly Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firefly Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
